Skip to main content
GutCited

Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans.

I Sakamoto, M Igarashi, K Kimura, A Takagi, T Miwa et al.
Other The Journal of antimicrobial chemotherapy 2001 309 citazioni
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'pmid\u003D11328791'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Tipo di studio
Controlled Clinical Trial
Dimensione del campione
31
Popolazione
H. pylori-infected subjects
Durata
8 weeks
Intervento
Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. LG21 yogurt daily for 8 weeks
Comparatore
Before-after comparison
Esito primario
H. pylori suppression (UBT, pepsinogens)
Direzione dell'effetto
Positive
Rischio di bias
Moderate

Abstract

To examine the efficacy of Lactobacillus gasseri OLL2716 (LG21) as a probiotic for Helicobacter pylori in humans, 31 subjects infected with the bacterium ingested yogurt containing LG21 daily for an 8 week period. The [(13)C]urea breath test and assays of serum pepsinogens revealed a significant improvement following LG21 treatment. LG21 was thus determined to be effective in both suppressing H. pylori and reducing gastric mucosal inflammation.

TL;DR

LG21 was determined to be effective in both suppressing H. pylori and reducing gastric mucosal inflammation and a significant improvement following LG21 treatment.

Used In Evidence Reviews

Similar Papers